Cleve Jones is an American human rights activist, author and lecturer whose work has spanned more than three decades. I had the opportunity to sit down with Jones to pick his brain about sex in San Francisco before AIDS, founding San Francisco AIDS Foundation, and how activists can take action with an incoming Donald Trump administration.
02 December 2016 | BETA blog
How a ten year battle to get travel cover for HIV patients changed the face of medical travel insurance.
02 December 2016 | World First
On this World AIDS Day, AVAC is drawing strength, as we always do, from our partners and from these issues, individuals and developments that shine light on the road ahead.
02 December 2016 | AVAC
The election of Donald Trump has left many people with HIV, their medical providers, and advocates feeling uncertain and anxious. Although Trump said little about HIV during the presidential campaign, his opposition to the Affordable Care Act and his conservative Cabinet picks suggest many of the advances of the Obama years may be rolled back. But all agreed that it is hard to predict specific details.
01 December 2016 | Bay Area Reporter
An extract from David France's new book How to Survive a Plague.
29 November 2016 | The Guardian
A question has always hung over the reaction of gay men to the plague that terrorized and decimated them in the 1980s and 1990s: Why did they not surrender? David France’s remarkable book tries to answer that question.
22 November 2016 | New York Times
A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials.
"It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."
17 November 2016 | HIV Prevention Justice Alliance
Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.
17 November 2016 | The Body
Gilead Sciences released this statement after considerable interest and concerns abut the forthcoming study of their new tenofovir formulation, TAF, for use in PrEP. The TAF/FTC pill is called Descovy(R). "Gilead Sciences is sponsoring a clinical trial, known as the DISCOVER study, to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as pre-exposure prophylaxis (PrEP). F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP...."
16 November 2016 | Gilead Sciences
Trump did not mention HIV/AIDS in his campaign speeches and platform. What does this mean in terms of fighting the epidemic during the next four years? Below we compile a list of comments and press releases from HIV advocates and AIDS service organizations.
10 November 2016 | Poz